Last reviewed · How we verify
Sertraline (SRT)
Sertraline selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Sertraline selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | Sertraline (SRT) |
|---|---|
| Also known as | Zoloft |
| Sponsor | Johns Hopkins University |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Sertraline is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and producing antidepressant and anxiolytic effects. The mechanism is thought to normalize mood and reduce anxiety symptoms over time with chronic administration.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Post-traumatic stress disorder
- Social anxiety disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
- Insomnia
- Sexual dysfunction
- Somnolence
- Dry mouth
Key clinical trials
- fMRI Study of Treatment Changes in Major Depression (NA)
- Child and Adolescent Anxiety Disorders (CAMS) (PHASE3)
- Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |